Stocks · News reference
Elevance Health (NYSE:ELV) Affirms FY2026 expected to be more than $27.00 vs $26.91 Est..
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
CVS Health's Health Services segment demonstrated strong Q2 2026 performance with revenues rising 11.5% to $51.8B and adjusted operating income climbing 10%. Health Care Delivery revenues jumped nearly 23% driven by Oak Street Health, while Pharmacy Services benefited from favorable drug mix and strong new sales of $6B. The company maintained its full-year 2026 outlook despite 340B program adjustments.
Centene Corporation is simplifying its Medicare Advantage footprint and emphasizing dual-eligible members to improve portfolio quality and margins. The company's Medicare segment health benefits ratio improved to 89.5% in Q2 2026, with MA moving closer to breakeven. For 2027, Centene aims to achieve breakeven or better MA results through medical-cost control, Stars execution, and SG&A management.
Crude jumped 6% and 30-year Treasury yields hit levels last seen in 2007 as a hot PPI print pushed Fed rate-hike odds toward 70% ahead of Friday's CPI.
Elevance Health shares are jumping Thursday after the company reaffirmed its FY26 earnings guidance ahead of a series of investor meetings.